The Prolieve System Website The Prolieve system provides a 45-minute in-office treatment that combines our microwave thermotherapy capability with a proprietary balloon compression technology to both heat the prostate and dilate the prostatic urethra. The purpose of the Prolieve...Read More
Our goal is to improve outcomes and standards of care in cancerous and non-cancerous treatments. Clinical studies have demonstrated that when used in conjunction with chemotherapy for breast cancer, Medifocus’ patented APA system can significantly increase tumor shrinkage by...Read More
Medifocus develops and commercializes minimally invasive treatment systems used in treatment of cancerous and benign tumors, and enlarged prostate, medically known as Benign Prostatic Hyperplasia (“BPH”). The Company owns two technology platforms with comprehensive...Read More
Our treatment is designed with patients' needs and comfort in mind.
Medifocus, Inc. (TSXV-MFS, OTC-MDFZF) develops and commercializes minimally invasive treatment systems used in treatment of cancerous and benign tumors, and enlarged prostate, medically known as Benign Prostatic Hyperplasia (“BPH”). The Company owns two technology platforms with approximately 100 issued and pending US and international patents:ReadMore
Our Prolieve Thermodilatation System was originally developed and commercialized by the current Medifocus management, product development, clinical and regulatory teams. In June 2012, Medifocus reached an agreement with Boston Scientific for the purchase of all of the assets of its Prolieve business,including all Prolieve inventory, the Rocky Mountain MobileReadMore
News Releases & Events 2014
• 10/23 Medifocus Inc. Announces Its Sponsorship at the VM Medical 20th Anniversary Breast Cancer Conference October 23rd